Surgeons prefer 3-cycle HA viscosupplement injections over the new 1-cycle injections

By

 
Hyaluronic Acid Products from Genzyme, Sanofi-Aventis Preferred Among Orthopedic Surgeons, According to Survey (press release)
According to a comprehensive global survey of orthopedic surgeons conducted by iData Research (www.idataresearch.net), the leading authority in medical device and pharmaceutical market research, orthopedic surgeons prefer 3-cycle hyaluronic-acid viscosupplementation (HA) treatment in the U.S., Europe and Latin Ameica, but are willing to try single-injection products such as Synvisc-One from Genzyme and MONOVISC from Anika Therapeutics.
Clinical efficacy and saf...

Get access to full posts newsletters, trends, and market reports for only subscribe for $1/day.
Hit the SUBSCRIBE button at the top of the homepage.